Shineco and BICC Partner to Promote On-Chain Cell Assets Across Multiple Institutions and Scenarios.

Shineco, a manufacturer of induced pluripotent stem cell technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. The partnership aims to advance the RWA ecosystem from "technical on-chain integration" to "real-world application" by standardizing cell assets and exploring verifiable application paths within a compliance framework.

Shineco Inc. (NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. The partnership aims to advance the RWA (Regenerative and Wellness Assets) ecosystem from "technical on-chain integration" to "real-world application" by standardizing cell assets and exploring verifiable application paths within a compliance framework.

The collaboration builds on Shineco's previous initiatives, including the establishment of a Cell Digital Division, signing an agreement with Plus Me Limited for on-chain cell asset management and marketing ecosystems, and acquiring a 51% stake in Xi'an Dong'ao Health Management Co., Ltd. These efforts lay a solid foundation for the digital application of cell assets. Plus Me will provide full-lifecycle digital management for Shineco's compliant mesenchymal stem cells on the Ethereum mainnet, generating "digital identities" and issuing ERC-1400/ERC-20 standard "Cell Reimbursement Vouchers." BICC's iPSC stem cell storage services will be integrated into Shineco's blockchain system, allowing users to redeem their vouchers in designated BICC scenarios [1].

Shineco's blockchain integration of stem cell assets creates a novel cross-enterprise redemption ecosystem. However, technical and regulatory hurdles remain substantial. Creating compliant digital representations of biological assets requires overcoming complex technical, regulatory, and practical hurdles across multiple jurisdictions. The partnership attempts to address this by dividing responsibilities: Shineco handling cell quality, Plus Me managing blockchain compliance, and BICC providing distribution infrastructure [1].

The new BICC partnership significantly expands this ecosystem by adding 3,000+ sales representatives and multiple Asian service centers to Shineco's network, potentially solving the logistical challenges of cross-regional cell therapy delivery. BICC's clinically validated wound-healing solutions, serum-free media patents, cell banking services, iPSC-derived therapies, and exosome delivery technology will synergize with Shineco's extracellular vesicle-derived products business, with technical parameters incorporated into the blockchain asset valuation system to enhance the technical endorsement of on-chain assets [1].

While innovative, the initiative's success depends on regulatory acceptance of tokenized biological assets, technical robustness of the blockchain implementation, and market adoption of this complex redemption system. This represents Shineco's strategic pivot from being merely a technical service provider to building global cell economy infrastructure – an ambitious but highly speculative transformation [1].

Shineco's CEO, Jennifer Zhan, stated, "The collaboration with BICC will tightly integrate 'standards and scenarios,' exploring verifiable application paths within a compliance framework. Shineco is transitioning from a single technical service provider to a global cell economy infrastructure provider. We welcome more biological cell companies to join the ecosystem and will continue to update on project progress" [2].

BICC Pte Ltd, founded in 2024, is an innovative biotechnology holding company that unites a world-class team of scientists and medical experts specializing in stem cell treatments and artificial intelligence. With a strategic presence across Asia, BICC leverages its proprietary stem cell technologies, such as patented serum-free media, iPSC-derived therapies, and clinically proven wound-healing applications, alongside personalized cell banking services [2].

References:
[1] https://www.stocktitan.net/news/SISI/shineco-nasdaq-sisi-bicc-from-tech-on-chain-to-global-redeemability-g4ks0zkl4ebt.html
[2] https://www.prnewswire.com/news-releases/shineco-nasdaq-sisi--bicc-from-tech-on-chain-to-global-redeemabilityrwa-ecosystem-takes-off-for-long-term-growth-302538261.html